Tirzepatide
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2, Overweight, Obesity
Trial Timeline
Jan 14, 2026 → Oct 1, 2026
NCT ID
NCT07299084About Tirzepatide
Tirzepatide is a phase 1 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07299084. Target conditions include Diabetes Mellitus, Type 2, Overweight, Obesity.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 2 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07438444 | Approved | Recruiting |
| NCT07299084 | Phase 1 | Recruiting |
| NCT07247084 | Approved | Recruiting |
| NCT06857942 | Approved | Recruiting |
| NCT06864026 | Approved | Recruiting |
| NCT06635057 | Approved | Active |
| NCT05912621 | Phase 2 | Recruiting |
| NCT05978713 | Phase 1 | Completed |
| NCT05810597 | Phase 1 | Completed |
| NCT05706506 | Approved | Completed |
| NCT04844918 | Phase 3 | Completed |
| NCT04847557 | Phase 3 | Completed |
| NCT04657003 | Phase 3 | Completed |
| NCT04660643 | Phase 3 | Completed |
| NCT04657016 | Phase 3 | Completed |
| NCT04050670 | Phase 1 | Completed |
| NCT04004988 | Phase 1 | Completed |
| NCT03940742 | Phase 1 | Completed |
| NCT03482024 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2